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Abstract
Background: Macular telangiectasia type 2 (MacTel) is a rare, heritable and largely untreatable retinal disorder,
often comorbid with diabetes. Genetic risk loci subtend retinal vascular calibre and glycine/serine/threonine
metabolism genes. Serine deficiency may contribute to MacTel via neurotoxic deoxysphingolipid production;
however, an independent vascular contribution is also suspected. Here, we use statistical genetics to dissect the
causal mechanisms underpinning this complex disease.
Methods: We integrated genetic markers for MacTel, vascular and metabolic traits, and applied Mendelian
randomisation and conditional and interaction genome-wide association analyses to discover the causal
contributors to both disease and spatial retinal imaging sub-phenotypes.
Results: Genetically induced serine deficiency is the primary causal metabolic driver of disease occurrence and
progression, with a lesser, but significant, causal contribution of type 2 diabetes genetic risk. Conversely, glycine,
threonine and retinal vascular traits are unlikely to be causal for MacTel. Conditional regression analysis identified
three novel disease loci independent of endogenous serine biosynthetic capacity. By aggregating spatial retinal
phenotypes into endophenotypes, we demonstrate that SNPs constituting independent risk loci act via related
endophenotypes.
Conclusions: Follow-up studies after GWAS integrating publicly available data with deep phenotyping are still rare.
Here, we describe such analysis, where we integrated retinal imaging data with MacTel and other traits genomics
data to identify biochemical mechanisms likely causing this disorder. Our findings will aid in early diagnosis and
accurate prognosis of MacTel and improve prospects for effective therapeutic intervention. Our integrative genetics
approach also serves as a useful template for post-GWAS analyses in other disorders.
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Background
MacTel disease and previous GWAS study
Macular telangiectasia type II (MacTel [1]) is a rare
(0.045–0.1% prevalence) degenerative eye disease affect-
ing the macula [2, 3]. MacTel is bilateral and progres-
sively affects visual acuity [4, 5], reading ability [6] and
vision-related quality of life [7, 8]. A successful phase II
clinical trial has recently been reported for an intravit-
real encapsulated cell therapy implant, showing efficacy
in slowing the disease progression [9]. However, less in-
vasive, non-surgical and more economical therapies are
lacking. Given the rarity of MacTel and its subtle clinical
signs, requiring several ophthalmological diagnostic
methods, MacTel has been largely under/misdiagnosed
[4]. Hence, further insight into the genetic basis of Mac-
Tel is key for accurate diagnosis, identifying future ther-
apies, developing predictive models for the disease and
increasing prognostic accuracy.
We previously published the first genome-wide associ-
ation study on 476 MacTel patients and 1733 controls
[10–12], identifying and replicating five loci. A single
nucleotide polymorphism (SNP) at locus 5q14.3
(rs73171800) showed the strongest association with the
disease and was previously identified to be associated
with the quantitative traits of retinal venular and arterial
calibre [13, 14]. The other four loci, 1p12 (rs477992),
2q34 (rs715), 7p11.2 (rs4948102) and 3q21.3
(rs9820286), were implicated in glycine and serine me-
tabolism [15, 16]. Importantly, loci 3q21.3 and 7p11.2
did not reach genome-wide significance, and the SNPs
at locus 3q21.3 were only in proximity, but not in link-
age disequilibrium (LD), with those associated with Mac-
Tel. We additionally measured and found significant
depletion of serum serine, glycine and threonine in Mac-
Tel patients compared to controls. These data provided
the first insight into the genetic complexity underpin-
ning MacTel and highlighted the potential involvement
of metabolic and vascular trait disturbances in disease
aetiology.
Glycine and serine are involved in many fundamental
biochemical reactions. Pathogenic variants in genes in-
volved in serine and glycine synthesis lead to severe con-
genital disorders such as phosphoglycerate dehydrogenase
deficiency (PHGDH, 601815) and glycine encephalopathy
(GLDC, 605899). Glycine and serine can be synthesised
from one another, from other metabolic compounds or
obtained through dietary intake.
A recent study reported the co-occurrence of MacTel in
patients with a rare neuropathy, hereditary sensory and
autonomic systemic neuropathy type I, or HSAN1 (162400)
[17]. This neuropathy results from pathogenic loss of func-
tion variants in the enzyme serine palmityltransferase, lead-
ing to the accumulation of neurotoxic deoxysphingolipids.
A similar accumulation of deoxysphingolipids was
demonstrated in MacTel patients but, unlike HSAN1, was
attributed to systemic serine deficiency.
MacTel is often comorbid with type 2 diabetes (T2D)
[18]. It is unknown whether traits such as metabolite
abundances, T2D or retinal vascular calibre, now known
to be associated with MacTel, are causative or merely as-
sociated with the disease for other reasons. Causation
hypotheses are now routinely investigated using Mendel-
ian randomisation (MR). MR borrows from instrumental
variable analysis and assumes that if a disease is caused
by a particular intermediate phenotype, and the latter is
caused by genetic variants, then the same genetic vari-
ants should be also associated with the disease [19–21].
Genetic variants involved in retinal vascular calibre traits
and T2D have been previously identified [13, 14, 22] and
the largest metabolomic GWAS meta-analysis to date
recently identified almost 500 loci that are associated
with differences in 142 serum metabolite levels in
humans [23, 24]. The results from these studies can be
used to investigate causal drivers of MacTel susceptibil-
ity via the MR approach.
Progress in MacTel diagnosis and treatment is compli-
cated by the lack of clear indicators of early stages and
by the substantial inter-patient and interocular hetero-
geneity of retinal phenotypes. Apportioning genetic vari-
ation to separate retinal malformations has the potential
to shed light on the different biological mechanisms via
which each locus contributes to the disease. Performing
joint genetic and retinal phenotypic data thus investi-
gates whether different retinal abnormalities are conse-
quences of common or largely independent biological
perturbations.
In this study, we test for the causality of several traits
on MacTel disease (Fig. 1a). We exploit independent
studies on MacTel-related traits to increase discovery
power in our disease cohort, and both identify new dis-
ease loci while further resolving previously identified loci
(Fig. 1b). We use extensive retinal phenotypic data from
MacTel patients to identify key genetic drivers of specific
subphenotypes (Fig. 1c). We collate genetic loci into
functional groups by testing their combined effects on
ocular spatial phenotypes (Fig. 1d). This study represents
the first integrated analysis of MacTel genotypic data
with MacTel-related traits as well as retinal imaging
phenotypic data. Our study serves as a model for post-
GWAS studies with phenotyping datasets.
Methods
Unless otherwise stated, all statistical and computational
analyses were performed using the R statistical software,
version 3.5.1. False discovery rate (FDR)-corrected p
values less than 0.05 were considered statistically signifi-
cant. For genome-wide association analyses, uncorrected
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p values less than 5e−8 were considered genome-wide
significant.
Study participants
We recruited cases and controls at 23 participating clin-
ical centres in seven countries (Australia, Germany,
France, the UK, Switzerland, Israel and the USA). In-
formed written consent was obtained in accordance with
the ethics protocols for human subjects approved by the
appropriate governing body at each site in accordance
with the Declaration of Helsinki as previously described
[10]. Protocols and records of consent were centrally
managed by the EMMES Corporation. The data was col-
lected under IRB approved protocols, and all participants
signed informed consents. A list of the ethics boards
granting approval for human subject enrolment is avail-
able in Additional file 1: Supplementary Methods.
DNA samples and SNP genotyping
Genotypic data was available for 476 MacTel patients
and 1733 controls. SNPs were genotyped using the
Illumina 5.0M chip as described previously [10]. Genetic
predictors for metabolites and retinal vascular calibre
were provided by the corresponding authors of each
study [13, 14, 23, 24].
Mendelian randomisation procedures
To perform Mendelian randomisation analysis on Mac-
Tel with metabolites, T2D and retinal vasculature, we
used the allele score method for individual-level genetic
data as described in section 3.1 by Burgess et al. [25].
This particular approach was selected because we have
access to individual-level genetic data, our instruments
were independent and instrument variable weights were
externally and independently generated. For each metab-
olite and trait, only the top significant SNP at each
genome-wide significant locus was used, with all SNPs
independent of each other (no LD between SNPs within
instruments). Using a p value threshold of 5e−8, we ex-
tracted SNPs significantly associated with serum metab-
olite concentrations or other traits of interest (retinal
venular calibre, retinal arteriolar calibre and T2D). We
Fig. 1 Study conceptual map. Each panel represents a study aim and depicts the data and the analysis technique used. Data is presented as
pastel colour pieces with black typing while analysis techniques are presented as darker panels with white writing. MacTel genetics refers to
individual-level SNP data available from our previous GWAS study. MacTel GWAS refers to the MacTel GWAS summary statistics. Vasculature GWAS
refers to the summary statistics data available from two previous retinal vasculature calibre genetic studies [13, 14]. Metabolomics GWAS refers to
summary statistics data available from a recently published metabolomics GWAS [23, 24]. T2D GWAS refers to summary statistics data available
from GWAS study on T2D [22]
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estimated the metabolic polygenic risk scores (mPRS)
and traits polygenic risk scores (tPRS) (Additional file 2:
Table S1) for each subject by using the SNP magnitudes
as weights (Additional file 1: Supplementary Methods).
Using logistic regression models, we tested for the asso-
ciation between mPRS or tPRS and MacTel susceptibil-
ity. This analysis was corrected for genetically
determined sex at birth and the first principal compo-
nent to account for batch effects including population
stratification, as in our previous publication [10]. We
used Benjamini-Hochberg multiple testing correction to
control the false discovery rate threshold of 5%. A condi-
tional modelling approach was used to identify mPRSs
independently associated with the disease. Specifically,
the most significant mPRS was iteratively added as a co-
variate in the regression model until no mPRS was sig-
nificant after FDR correction. The pleiotropic effect of
the instrument variables used to create the mPRSs and
tPRSs was assessed by performing the Egger test be-
tween the effect size of the instrument variables on both
MacTel and the metabolites/trait risk [26]. Lastly, we
generated visual representations of the correlation be-
tween the effect sizes for all significant traits to inspect
the relationship for the robustness of the regression ana-
lysis, to ensure that there were no outliers driving the
results.
Conditional and interaction GWAS
Conditional GWAS were performed by including mPRSs
or tPRSs in the logistic regression models as covariates.
For the interaction GWAS, an interaction term was in-
cluded for each SNP and the mPRS or tPRS combination
of interest. Each model also included genetically deter-
mined sex at birth and the first principal component
[10]. Analyses were performed using Plink v1.9 [27]. Re-
sults from the conditional and interaction GWAS were
analysed using FUMA [28]. LocusZoom plots were pro-
duced using the LocusZoom software [29].
Retinal phenotypes
We used longitudinal retinal phenotypic data on 1716
patients (3410 eyes) collected from Natural History Ob-
servation and Registry studies of Macular Telangiectasia
[30]. The data consisted of 143 spatial measurements of
retinal phenotypes (Additional file 3: Table S2). A de-
tailed description of the corresponding methods can be
found elsewhere [30]. Each phenotype was measured in
9 different sub-fields of the retina (defined by the ETDR
S grid [31] Additional file 1: Figure S1). The phenotype
data was cleaned by performing missing data imputation
(Additional file 1: Supplementary Methods). The cleaned
dataset contained 119 phenotypes that were collapsed
into 30 biologically relevant endophenotypes using factor
analysis (Additional file 1: Supplementary Methods).
Investigating the relationship of retinal endophenotypes
with genetic drivers
We tested for the association between retinal endophe-
notypes and significant disease-associated mPRSs, tPRSs
and previously prioritised SNPs. The dataset containing
retinal endophenotypes and genetic information in-
cluded 3280 observations from 455 MacTel patients
(907 eyes in total) with an average of 3.6 observations
per eye over 10 years. Association testing was performed
using a linear mixed model approach, assuming an addi-
tive effect of SNP alleles that increased MacTel risk. p
values were corrected using an adaptive Benjamini-
Hochberg procedure [32]. Further details are provided in
Additional file 1: Supplementary Methods.
Results
Discovering key drivers of MacTel disease: metabolites
The MR procedure (Fig. 1a) applied to the metabolite
panel highlighted 14 metabolic PRSs significantly associ-
ated with MacTel (Table 1, Additional file 4: Table S3).
The two most significant metabolites were serine PRS
and glycine PRS. In contrast to the metabolomics results
from our previous metabolomics study with directly
measured metabolites, threonine PRS was not signifi-
cant. Other significant metabolites included arginine
PRS, phenylalanine PRS and phosphatidylcholine species
PRSs. Alanine PRS was borderline significant.
The significant PRSs correlated with each other in our
sample (Additional file 1: Figure S2), mirroring correla-
tions observed with directly measured metabolite abun-
dances. When all PRSs were re-tested in a model
including serine PRS as a covariate, glycine PRS was the
only associated metabolite (Additional file 4: Table S3).
However, in this setting, glycine PRS significance de-
creased substantially (FDR = 0.022), while serine PRS
remained strongly significant (FDR = 3.27e−11). No other
metabolic PRS remained significant once serine PRS and
glycine PRS had been included (Additional file 4: Table
S3). Further, MR testing of a broader set of 248 metabolic
PRSs abundances using results from Shin et al. [16, 33]
(Additional file 2: Table S1) found a few additional signifi-
cant univariate contribution from other metabolites (Add-
itional file 1: Supplementary Materials and
Additional file 5: Table S4). However, none remained sig-
nificant after inclusion of serine PRS as a covariate.
Discovering key drivers of MacTel disease: T2D and
retinal vasculature
T2D PRS was significantly associated with MacTel, as
were both arteriolar and venular calibre PRS when tested
separately. However, the vasculature trait results were
driven by a single SNPs: rs2194025 (for arteriolar
calibre) and rs17421627 (for venular calibre), both in
strong LD with SNP rs73171800 at 5q14.3 previously
Bonelli et al. Genome Medicine           (2021) 13:39 Page 4 of 11
identified in our original GWAS [10]. When including
both vascular traits in the same model, only arteriolar
calibre remained significant, due to the reduced number
of SNPs (N = 2) used to construct that PRS (Additional
file 1: Figure S3). When PRSs for retinal arteriolar
calibre and T2D were included in a model with glycine
and serine PRSs, all remained significant.
As a quality control analysis, we compared the effect
sizes for each instrumental SNP on both MacTel and
the metabolites or traits to inspect for potential SNP
outlier effects of pleiotropy (Fig. 2). A negative, linear re-
lationship was detected between the effect on the meta-
bolic abundance and MacTel risk for the SNPs used to
define glycine and serine. A positive relationship was
Table 1 Significant associations between mPRS and tPRS and MacTel. Regression coefficients are presented in the “Beta” column.
Odds ratios (OR) are relative to a single standard deviation increase on the mPRS/tPRS scale. Odds ratios 95% confidence intervals
are shown in the “95% C.I.” column. Benjamini-Hochberg-adjusted p values are presented under the “p value” column
Metabolite/Trait PRS Beta OR 95% C.I. p value Biochemical Family
Serine −0.65 0.52 0.46–0.58 8.38E−28 Amino acids and biogenic amines
Glycine −0.58 0.56 0.50–0.63 5.44E−19 Amino acids and biogenic amines
Lysophosphatidylcholine acyl C14:0 0.21 1.23 1.11–1.37 2.48E−03 Glycerophospholipids
Phosphatidylcholine diacyl C32:1 0.21 1.23 1.11–1.37 2.48E−03 Glycerophospholipids
Phosphatidylcholine diacyl C34:1 0.21 1.23 1.11–1.37 2.48E−03 Glycerophospholipids
Phosphatidylcholine with acyl-alkyl residue C38:1 0.20 1.22 1.10–1.36 2.97E−03 Glycerophospholipids
Arginine 0.17 1.18 1.07–1.31 2.83E−02 Amino acids and biogenic amines
Phenylalanine −0.17 0.85 0.76–0.94 2.85E−02 Amino acids and biogenic amines
Arteriolar retinal calibre 0.32 1.38 1.25–1.52 2.22E−10 Vasculature trait
Venular retinal calibre 0.18 1.19 1.08–1.32 7.00E−04 Vasculature trait
T2D 0.17 1.19 1.07–1.33 7.72E−04 Comorbidity
Fig. 2 Effect size comparisons between MacTel and specific trait of SNPs used to define mPRS and tPRS. Each dot represents a SNP. Each panel
represents a trait and contains the SNPs that were found to have a genome-wide significant effect on that trait. The x-axis captures the effect
sizes of the SNPs on the trait while the y-axis captures the effect of the same SNPs on MacTel risk. The blue line represents a simple regression
line between the two. Metabolites or traits causally affecting the disease are expected to have correlated effect sizes. Colour of the dots
represents chromosomal positions where different chromosomes are represented by different colours
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observed for T2D and vasculature traits, while no rela-
tionship was detected for threonine which was used as a
control trait, where no significant association was ob-
served. We additionally observed that the regression line
for all significant traits except the vasculature related
traits, did not have intercept terms that were signifi-
cantly different from 0 (b0,serine = − 0.07, p = 0.2; b0,gly-
cine = 0.070, p = 0.131; b0,T2D = 0.002, p = 0.88) suggesting
a non-pleiotropic effect of the instruments used to test
such traits [26] (Fig. 2). The same conclusion was drawn
when glycine and T2D SNPs considered to have poten-
tial outlier effects were removed.
Conditional and interaction GWAS
To uncover genetic correlates of MacTel independent of
glycine and serine, we performed a GWAS conditioning
on these mPRS (Fig. 1b). This analysis identified four
genome-wide significant peaks (Additional file 1: Figure
S4 a) and presented minimal inflation factor (1.029)
(Additional file 1: Figure S4 e).
As expected, the original signal on locus 5q14.3
(rs73171800) related to vascular calibre remained signifi-
cant, confirming the independence of this locus from
genetic drivers of serine and glycine. A second genome-
wide significant signal on locus 3p24.1 (rs35356316, p =
3.10e−08) was identified and was situated in a “gene des-
ert” proximal to the genes EOMES and SLC4A4. An-
other single SNP in very close proximity to rs35356316
reached genome-wide significance as in the original
MacTel GWAS study [10] but was believed to be a false
positive, given the lack of LD with any other significant
SNP (Additional file 1: Figure S4 b).
The remaining two conditionally significant SNPs tagged
independent signals in locus 19p13.2 (Additional file 1: Fig-
ure S4 c-d). SNP rs36259 is an exonic non-synonymous
SNP located in the CERS4 gene which achieved close to
genome-wide significance (p = 6.270e−08) and was nomin-
ally significant in our original study (p = 1.69e−7). In close
proximity, we found an independent intergenic SNP
rs4804075 (p = 3.72e−07) which lacked evidence of an
eQTL effect on any neighbouring genes and which did not
reach genome-wide significance. These results remain sig-
nificant when conditioning on SNP rs73171800 (locus
5q14.3) and T2D PRS.
We performed additional GWAS analyses testing for
interactions between all SNPs with serine, glycine, T2D
PRSs and SNP rs73171800 (Fig. 1b). However, no further
significant interacting loci were found (Additional file 1:
Figure S5 a-d).
Effect of key drivers on retinal endophenotypes
Given the small sample size of the endophenotypic data
(N = 455), we only tested for the association between
endophenotypes and glycine, serine and T2D PRSs, as
these bore the clearest association with disease aetiology
(Fig. 1c, Additional file 6: Table S5). No significant asso-
ciation between glycine or T2D PRSs and endophenotypes
was found after correcting for serine PRS, and we, there-
fore, excluded them from additional testing. High serine
PRS levels were found to be protective against loss of ret-
inal transparency, leakage at the outer capillary network
and the retinal pigment epithelium (RPE) in MacTel pro-
gression areas and leakage at the RPE in the MacTel area.
We also found suggestive significance for protection from
perivascular pigment clustering in the MacTel area and
progression area. Higher serine PRS levels were associated
with protection from macular thinning in the MacTel area
and inferior inner area, and suggestive protection on nasal
inner area and foveal area.
Determining the effects of GWAS loci on endophenotypes
To determine the likely functional impacts of the ori-
ginal GWAS loci, we tested for the associations with ret-
inal endophenotypes (Fig. 1d, Fig. 3, Additional file 6:
Table S5). No associations remained significant after
correction for multiple testing due to the modest sample
and effect sizes of individual SNPs on disease endophe-
notypes. Using a nominally (uncorrected) significant p
value threshold denoted p* < 0.05 in an exploratory ap-
proach, we observed that locus 1p12 (rs477992) was as-
sociated with an increased risk of perivascular pigment
clustering in the progression area, but protected against
the risk of blunted vessels. Furthermore, locus 2q34
(rs715) increased the risk of macular thinning in the
MacTel area and nasal inner area and the risk of perivas-
cular pigment clustering in the MacTel area. Finally, the
MacTel risk allele at locus 7p11.2 (rs4948102) increased
the risk of retinal transparency, leakage at the RPE in
both the MacTel area and progression area, as well as
the presence of inner empty spaces and EZ break. This
locus however protected against leakage in the outer
layer of the foveal area.
These three loci, which converge on glycine/serine
metabolism (1p12/rs477992/PHGDH, 2q34/rs715/CPS1
and 7p11.2/rs4948102/PSPH), all demonstrated an over-
all susceptibility increment to RPE endophenotypes and
other macular phenotype risks, lending further support
for their role, despite not attaining significance after p
value adjustment.
Interestingly, the MacTel risk allele at locus 3q21.3
(rs9820286) was only associated with protection from
retinal disease endophenotypes. Specifically, locus 3q21.3
was associated with protection against retinal holes, ret-
inal detachment, perivascular pigment clustering in the
MacTel area and progression areas; leakage at the RPE
level in the MacTel area and progression area; and foveal
slope flattening in MacTel area, inferior inner area, and
nasal inner area.
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Locus 5q14.3 (rs73171800) corresponded to pro-
tection against macular thinning in the foveal area
and nasal-inferior outer areas and increased risk of
foveal flattening in the nasal inner area. Clustering
the loci using hierarchical clustering on their re-
gression coefficients (Figure S6) highlighted the
unique endophenotype effect profiles of the 5q14.3
(rs73171800) and 3q21.3 (rs9820286) loci, and
their distinctiveness in comparison with the other
three loci, known to act on the serine/glycine
pathway.
Discussion
This study exploited well-powered publicly available
GWAS data from traits of interest as well as deep retinal
phenotyping data to further investigate the genetic aeti-
ology of MacTel, a rare retinal disorder for which the
first GWAS was only recently performed [10].
Mendelian randomisation and publicly available data
were used to “genetically estimate” abundances of differ-
ent metabolites. Although all PRSs in this study were
generated using estimated SNP allele dosage effects from
blood-based metabolomic studies rather than the retina,
Fig. 3 Association plot summarising all nominally significant association between MacTel SNPs and the endophenotypes (Additional File 6: Table
S5). SNPs are divided into categories based on MR results. Each dot represents the nominal p-value for each association between all SNPs and
endophenotypes. Red dots indicate that MacTel risk alleles for that SNP also increases the risk of the retinal phenotype, while blue dots indicate a
reduced risk. The dashed line represents the nominal significance of p = 0.05. The top right corner displays the ETDRS grid for the right eye (OD)
[31] used to divide the endophenotypes into 9 retinal areas: 1: foveal area, 2: superior inner area, 3: nasal inner area, 4: inferior inner area, 5:
temporal inner area, 6: superior outer area, 7: nasal outer area, 8: inferior outer area and 9: temporal outer area. Although definitions vary across
the literature, for simplicity, in this manuscript, we define the pink area as the “MacTel [onset] area” while the green areas are MacTel
“progression areas”
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we believe that our results represent a useful approach
for interrogating other retinal disorders.
We found serine depletion as the strongest causal
driver of MacTel risk, with an association magnitude
much greater than those observed when using single
SNPs. The direction of the association between serine
PRS and MacTel agrees with the from direct serum
serine measurements reported previously [10], compel-
ling additional evidence for a causal association between
serine deficiency and MacTel. MacTel disease odds dou-
bled for every standard unit decrease in serine PRS, and
individuals in the lowest quintile of serine PRS presented
an OR of 6.34 for MacTel compared to individuals in
the top quintile. Our results also suggest a pronounced
role of serine depletion in disease progression. As this
analysis was applied only to MacTel patients and hetero-
geneity of retinal phenotypes may be under-represented,
serine PRS was nevertheless able to partly discriminate
between subjects with more advanced retinal abnormal-
ities and those without. For example, lower serine PRS
had an association with retinal greying in all retinal
areas, a phenotype not observed in all MacTel patients
[4]. Serine PRS also affected retinal thinning in the tem-
poral parafoveal area, a marker of photoreceptor degen-
eration. Our results suggest a plausible biochemical
explanation for differences in disease heterogeneity and
progression. However, we acknowledge that our study
used only aggregated retinal phenotypes and proxy mea-
sures of progression. Longitudinal data documenting
progression is now required to confirm these findings.
High concentrations of deoxy-sphingolipids, a byproduct
of serine deficiency, have recently been shown to cause
MacTel [17]. Our results provide evidence that genetic-
ally encoded serine depletion is causal for MacTel,
which likely contributes to the disease by promoting
deoxy-sphingolipid biosynthesis [17].
The metabolomics study performed by Lotta and col-
leagues [23, 24] has a sample size up to ~ 80 times
greater than the MacTel discovery GWAS case sample
size, although this varied by metabolite. With such a
substantially greater sample size the metabolomics study
was able to not only define the glycine and serine PRS
but to also to compare their contribution to MacTel.
Lotta and colleagues identified several pleiotropic SNPs
that affect both glycine and serine abundance (4 out of 5
serine SNPs were also discovered to be genome-wide
significant SNPs for glycine). This is likely due to the
large correlation between these two metabolites. Previ-
ous metabolic studies have documented that glycine can
be turned into serine and vice versa. When included
along with serine PRS to predict MacTel, glycine PRS
decreased substantially in significance. This suggests that
the association between glycine PRS and MacTel may be
in effect, due to the shared genetic signal between this
metabolite and serine. We suspect that the glycine PRS
remained significant in the conditional MR approach be-
cause it contained SNPs that were also associated with
serine but were not discovered by Lotta and colleagues be-
cause of the smaller sample size available for this metabol-
ite (2.5 times smaller). Lastly, the previously observed
significant association of threonine to MacTel disease risk
[10] through direct metabolite assessments in MacTel pa-
tient’s serum may be due to its metabolic dependence on
glycine and serine, and thus a bystander effect.
SNP rs73171800 nominally affected macular thickness,
specifically, a protective effect of the C allele against
macular thinning, or an increase in macular thickness.
Interestingly, a large GWAS study previously found that
the G allele of SNP rs17421627—corresponding to the C
allele of SNP rs73171800 (LD with rs73171800 r2 =
0.67)—was significantly associated with increased macu-
lar thickness [34]. A targeted study of SNP rs17421627
demonstrated enhancer activity which modifies the ret-
inal vasculature [35]. Substituting the homologous zeb-
rafish locus with a construct containing rs17421627
resulted in enhancer activity and changed expression of
a proximal microRNA, mir-9-2 (homologous with hu-
man mir-9-5). Both mir-9-2 knock-down and endogen-
ous enhancer knock-out animals showed dysmorphic
retinal vasculature, indicating that rs17421627 may act
on miRNA expression to modify the formation of the
retinal vasculature in humans. Although we did not find
a convincing causal relationship between retinal vascular
calibre and MacTel, it may be that other features of the
vasculature, for example, leakage, branching or integrity,
are modified in rs17421627 carriers and account for the
gross differences in macular thickness. Further, deep
phenotyping of the retinal vasculature in these individ-
uals may yield the physiological basis for this phenotype
and its impact on MacTel.
We tried to increase discovery power compared to our
previous work by conditioning on serine, glycine and
T2D PRSs generated from much larger, independent
studies. This exploratory analysis revealed two genetic
contributors to MacTel which appear to be independent
of the serine metabolic risk. These two loci were already
found to be at least suggestively significant in our previ-
ous work, and as such, these loci should be considered
as being further prioritised with this additional statistical
evidence for the association. The locus 3p24.1, tagged by
SNP rs35356316, lies between EOMES (604615) and
SLC4A4 genes (603345). Interestingly, EOMES encodes a
transcriptional activator which is shown in mouse stud-
ies to interact with the retinal transcription factor
Pou4f2 [36]. The downstream gene SLC4A4 encodes a
sodium-coupled bicarbonate transporter which is
expressed in Müller glia and the RPE, and functions to
balance pH in the subretinal space [37]. Future GWAS
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with greater sample sizes should see both loci achieve
genome-wide significance without requiring conditional
analysis leveraging the PRS from other studies.
Conditional analysis revealed SNP rs36259 at locus
19p13.2 which tags an exonic, non-synonymous SNP lo-
cated within the gene CERS4 (615334), encoding a dihy-
droceramide synthase involved in sphingolipid
biosynthesis [38]. Just as serine depletion is associated
with defective sphingolipid synthesis, this locus may re-
duce sphingolipid production and thus contribute to
MacTel.
Type 2 diabetics are overrepresented amongst MacTel
patients [18]. We found a weak positive association be-
tween T2D PRS and MacTel risk. A possible explanation
for this is that T2D involves major perturbations of pa-
tient metabolism. Specifically, a recent meta-analysis of
metabolite abundances associated with pre-diabetes and/
or T2D, found that glycine depletion tends to occur in
this disease [39]. We show that glycine depletion is not
likely to be causative for MacTel and is likely to be a
consequence of metabolomic co-regularisation counter-
balancing the genetically induced serine depletion. We
speculate that diabetes may be a consequence rather
than a cause of the metabolic phenotype underlying
MacTel. Future MR studies may further dissect this
interaction but will require a more highly powered Mac-
Tel GWAS. Indeed, T2D risk remained significant even
after controlling for serine PRS and glycine PRS, which
indicates the possibility of a separate mechanism unre-
lated to glycine/serine metabolism.
Our analysis revealed that locus 3q21.3, previously be-
lieved to act on the disease by modifying serum glycine
and serine, is instead likely disconnected from these me-
tabolites, as is the case for loci 3p24.1 and 5q14.3, imply-
ing that additional potential disease mechanisms exist.
Conclusions
Our study demonstrates a likely causal contribution of
serine abundance in both disease aetiology and progres-
sion. We additionally identified genetic contributors that
are likely to act on disease development independently
from serine availability. Future studies of disease pro-
gression and experimental validation of serine dependent
and independent contributions will help to resolve the
complex aetiology of MacTel and hence target treat-
ments leading to increased efficacy.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13073-021-00848-4.
Additional file 1: Figure S1. Right (OD) and left (OS) eyes macula,
were divided into 9 areas according to the ETDRS grid 1. 1: foveal area, 2:
superior inner area (progression area), 3: nasal inner area (progression
area), 4: inferior inner area (progression area), 5: temporal inner area
(MacTel area), 6: superior outer area, 7: nasal outer area, 8: inferior outer
area, and 9: temporal outer area. Figure S2. Correlation between mPRS
that achieved multiple testing corrected significance (p < 0.05). Bigger
dots and saturated colour indicate stronger correlations. Blue indicates a
positive correlation while red indicates a negative one. Figure S3.
Comparison between SNPs effect on vasculature traits and MacTel. Each
dot is a SNP which was found to be significantly associated with a
vasculature trait. The x-axis represents the effect that the SNP has on the
particular trait while the y-axis displays the effect that the SNP has on
MacTel. Most SNPs have no effect on MacTel. The only two SNPs that
have an effect are the SNPs rs2194025 and rs17421627 which are very
close to each other and in strong LD with SNP rs73171800 (r2=0.94 and
r2=0.67). Figure S4. MacTel GWAS results conditioned by serine PRS and
glycine PRS. A) Manhattan plot. B) Locus zoom plot of the significant sig-
nal on locus 3p24.1. C) Locus zoom plot of the significant signal by SNP
rs36259 on locus 19p13.2. D) Locus zoom plot of the significant signal by
SNP rs4804075 on locus 19p13.2. E) QQ-plot of association p-values. Fig-
ure S5. MacTel interaction GWAS results. A) Manhattan plot showing
SNP interactions with serine PRS, B) Manhattan plot showing SNP interac-
tions with glycine PRS, C) Manhattan plot showing SNPs interaction with
SNP rs73171800 in locus 5q14.3, D) Manhattan plot showing SNP interac-
tions with T2D PRS. Figure S6. Loci clustering heatmap. This clustering
heatmap visualises the regression coefficients of each SNP on the endo-
phenotypes. Rows and columns of the heatmaps were ordered according
to the hierarchical clustering to give a visual representation of the similar-
ities. SNP rs73171800 (5q14.3) and SNP rs9820286 (3q21.3) have very dif-
ferent effects from the other four SNPs which show a more consistent,
shared pattern. Table S7. List of members and affiliations of the MacTel
consortium researchers.
Additional file 2: Table S1. SNPs and weights used to create mPRSs,
tPRSs, Shin et al mPRSs.
Additional file 3: Table S2. List of all phenotypes and measurement
methods used to create the endophenotypes.
Additional file 4: Table S3. List of all mPRS associations and
conditional mPRS association results.
Additional file 5: Table S4. List of all Shin et al mPRS associations
results.
Additional file 6: Table S5. Endophenotypes analysis results.
Additional file 7: Table S6. Endophenotypes compositions and
weights (available as .xlsx file). Phenotypes are presented in rows while
Endophenotypes are presented as columns. The weight that each
phenotype has on the endophenotype creation is presented in each cell
value.
Abbreviations
MacTel: Macular Telangiectasia Type 2; GWAS: Genome-wide association
study; SNP: Single nucleotide polymorphism; LD: Linkage disequilibrium;
HSAN1: Hereditary sensory and autonomic systemic neuropathy type 1;
T2D: Type 2 diabetes; MR: Mendelian randomisation; mPRS: Metabolic
polygenic risk score; tPRS: Trait polygenic risk score; FDR: False discovery rate;
Gly: Glycine; Ser: Serine; RPE: Retinal pigment epithelium
Acknowledgements
We are grateful to Dr. Luca Lotta and Dr. Claudia Langenberg for sharing
their summary results of metabolomics data and their extremely helpful
contributions. Dr. Saskia Freytag, Dr. Anna Quaglieri, Prof. Terry Speed, Prof.
Gordon Smyth, Dr. Mari Gantner, Dr. Kevin Eade, Dr. Martina Wallace, A/Prof.
Christian Metallo, Prof. Martin Friedlander, Dr. Tjebo Heeren, Dr. Mali Okada,
Dr. Sasha Woods, Prof. Marcus Fruttiger and Dr. Catherine Egan for their
extremely helpful contributions that greatly improved the quality of this
manuscript. We are especially grateful to Dr. Xueling Sim and Prof. Wong
Tien Yin for kindly sharing their summary data on retinal vascular calibre
traits.
MacTel Consortium members and their affiliations are provided in Table S7
(Supplemental Information).
Bonelli et al. Genome Medicine           (2021) 13:39 Page 9 of 11
Authors’ contributions
RB designed the study, performed all the statistical analyses, interpreted the
results and wrote the manuscript. BREA supervised the analyses, interpreted
the results and wrote the manuscript. LL provided the MR instruments and
supervised the MR analysis. TS supervised the analyses and cleaned the
genetics data. TEC supervised the statistical analysis. IL, TP, ACB and FBS
provided retinal data, helped design the study and helped in the
interpretation of the retinal phenotypes and results. CL provided the MR
instruments, supervised the MR analysis and interpreted the results. MB
designed the study, supervised all the statistical analyses, interpreted the
results and wrote the manuscript. All authors read and approved the final
manuscript.
Funding
We would like to acknowledge the funding support from the Lowy Medical
Research Institute. This work was also made possible through the Victorian
State Government Operational Infrastructure Support and Australian
Government National Health and Medical Research Council (NHMRC)
independent research Institute Infrastructure Support Scheme (IRIISS). RB was
supported by the Melbourne International Research Scholarship. BREA was
supported by an NHMRC Early Career Fellowship (1157776). MB was
supported by an NHMRC Senior Research Fellowship (1102971).
Availability of data and materials
The MacTel consortium genotypes for 678 samples (with consent) of the 704
samples genotyped as part of the discovery stage and that support the
findings of this study have been deposited in the European Genome-
phenome Archive (EGA), which is hosted by the European Bioinformatics In-
stitute and the CRG, under accession EGAS00001002249 (https://www.ebi.ac.
uk/ega/studies/EGAS00001002249) [11].
Controls genotype data from the project “NEI Age-Related Eye Disease Study
(AREDS)–Genetic Variation in Refractive Error Substudy” is available on dbGap
under accession phs000429, substudy of phs000001 (https://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000429.v1.p1) [12].
Ethics approval and consent to participate
Informed written consent was obtained in accordance with the ethics
protocols for human subjects approved by the appropriate governing body
at each site in accordance with the Declaration of Helsinki. Protocols and
records of consent were centrally managed by the EMMES Corporation. The
following ethics boards granted approval for human subject enrollment:
Quinze-Vingts, Paris, France: Comité de Protection des Personnes Hôpital
Saint-Antonie; Centre for Eye Research, Victoria, Australia: The Royal Victorian
Eye and Ear Hospital; QIMR Berghofer Institute of Medical Research, Queens-
land, Australia; Clinique Ophtalmolgie de Creteil, Paris, France: Comité de Pro-
tection des Personnes Hôpital Saint-Antonie; Hospital Lariboisiere, Paris,
France: Comité de Protection des Personnes Hôpital Saint-Antonie; Jules
Stein Eye Institute, UCLA, CA, USA: The UCLA Institutional Review Board;
Lions Eye Institute, Nedlands, Australia: Sire Charles Gairdner Group Human
Research Ethics Committee; Manhattan Eye, Ear and Throat Hospital, NY,
USA: Lenox Hill Hospital Institutional Review Board; Moorfields Eye Hospital,
London, UK: National Research Ethics Service; Retina Associates of Cleveland,
Inc., Cleveland, OH, USA: Sterling Institutional Review Board; Save Sight Insti-
tute, Sydney, Australia: South Eastern Sydney Illawarra Area Health Service
Human Research Ethics Committee–Northern Hospital Network; Scripps Re-
search Institute, La Jolla, CA, USA: Scripps Institutional Review Board; St. Fran-
ziskus Hospital, Munster, Germany: Ethik-Kommission der Arztekammer
Westfalen-Lippe und der Medizinishchen Fakultat der Westfallschen
Wilhelms-Universitat; The Goldschleger Eye Institute, Tel Hashomer, Israel:
Ethics Committee The Chaim Sheba Medical Center; The New York Eye and
Ear Infirmary, NY, USA: The Institutional Review Board of the New York Eye
and Ear Infirmary; The Retina Group of Washington, Olympia, WA, USA: West-
ern Institutional Review Board; University of Bonn, Bonn, Germany: Rheinische
Friedrich-Wilhelms-Universität Ethik-Kommission; University of Chicago, Chi-
cago, IL, USA: The University of Chicago Division of Biological Sciences–The
Pritzker School Institutional Review Board; University of Michigan, Ann Arbor,
MI, USA: Medical School Institutional Review Board (IRBMED); University of
Wisconsin, Madison, WI, USA: Office of Clinical Trials University of Wisconsin
School of Medicine and Public Health; The Wilmer Eye Institute of Johns
Hopkins University, Baltimore, MD, USA: Johns Hopkins School of Medicine
Office of Human Subjects Research; Scheie Eye Institute University of
Pennsylvania, Philadelphia, PA, USA: University of Pennsylvania Office of
Regulatory Affairs; University of Bern, Bern, Switzerland: Kantonale Ethikkom-
mission Bern; John Moran Eye University of Utah, Salt Lake City, UT, USA: The
University of Utah Institutional Review Board; Bascom Palmer Eye Institute
University of Miami, Miami, FL, USA: The University of Miami Human Subjects
Research Office; and Columbia University, New York, NY, USA: Columbia Uni-
versity Medical Center Institutional Review Board Category 4 waiver for re-
search involving specimens obtained from deidentified subjects. The Walter
and Eliza Hall Institute of Medical Research Human Research Ethics Commit-
tee confirmed that all research in this study meets the requirements of
negligible-risk research under the Australian National Statement on Ethical




The authors declare that they have no competing interests.
Author details
1Department of Medical Biology, The University of Melbourne, Parkville,
Victoria 3052, Australia. 2Population Health and Immunity Division, The
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052,
Australia. 3MRC Epidemiology Unit, University of Cambridge, Cambridge CB2
0SL, UK. 4The EMMES Corporation, Rockville, MD 20850, USA. 5Department of
Research and Development, Moorfields Eye Hospital NHS Foundation Trust,
London EC1V 2PD, UK. 6Department of Ophthalmology, Queen’s University,
Belfast BT7 1NN, UK. 7Inherited Eye Disease, Moorfields Eye Hospital NHS
Foundation Trust, London EC1V 2PD, UK. 8Department of Ophthalmology,
Hôpital Ophtalmique Jules-Gonin, Fondation Asile des Aveugles, University of
Lausanne, Lausanne, Switzerland.
Received: 8 July 2020 Accepted: 8 February 2021
References
1. Gass J. Some problems in the diagnosis of macular diseases. Symposium on
Retinal Diseases; 1977. p. 268–70.
2. Klein R, Blodi BA, Meuer SM, Myers CE, Chew EY, Klein BEK. The prevalence
of macular telangiectasia type 2 in the Beaver Dam Eye Study. Am J
Ophthalmol. 2010;150:55–62.e2.
3. Aung KZ, Wickremasinghe SS, Makeyeva G, Robman L, Guymer RH. The
prevalence estimates of macular telangiectasia type 2: the Melbourne
Collaborative Cohort Study. Retina. 2010;30:473–8.
4. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TFC, Peto T, et al.
Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77.
5. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of
classification and follow-up study. Ophthalmology. 1993;100:1536–46.
6. Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HPN.
Reading performance is reduced by parafoveal scotomas in patients with
macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2009;50:1366–70.
7. Lamoureux EL, Maxwell RM, Marella M, Dirani M, Fenwick E, Guymer RH. The
longitudinal impact of macular telangiectasia (MacTel) type 2 on vision-
related quality of life. Invest Ophthalmol Vis Sci. 2011;52:2520–4.
8. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, et al. The
National Eye Institute Visual Function Questionnaire in the Macular
Telangiectasia (MacTel) Project. Invest Ophthalmol Vis Sci. 2008;49:4340–6.
9. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, et al. Effect of
ciliary neurotrophic factor on retinal neurodegeneration in patients with
macular telangiectasia type 2: a randomized clinical trial. Ophthalmology.
2018; Available from: https://doi.org/10.1016/j.ophtha.2018.09.041.
10. Scerri TS, Quaglieri A, Cai C, Zernant J, Matsunami N, Baird L, et al. Genome-
wide analyses identify common variants associated with macular
telangiectasia type 2. Nat Genet. 2017; Available from: https://doi.org/10.103
8/ng.3799.
11. Scerri TS, Quaglieri A, Cai C, Zernant J, Matsunami N, Baird L, et al. Genome-
wide analyses identify common variants associated with macular
telangiectasia type 2. Euro Genome Phenome Archive. 2017; Available from:
https://www.ebi.ac.uk/ega/studies/EGAS00001002249.
Bonelli et al. Genome Medicine           (2021) 13:39 Page 10 of 11
12. Dwight S. et al. NEI Age-Related Eye Disease Study (AREDS) - genetic
variation in refractive error substudy.2015 Available from: https://www.ebi.a
c.uk/ega/studies/EGAS00001002249
13. Ikram MK, Sim X, Xueling S, Jensen RA, Cotch MF, Hewitt AW, et al. Four
novel loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation
in vivo. PLoS Genet. 2010;6:e1001184.
14. Sim X, Jensen RA, Ikram MK, Cotch MF, Li X, MacGregor S, et al. Genetic loci
for retinal arteriolar microcirculation. PLoS One. 2013;8:e65804.
15. Xie W, Wood AR, Lyssenko V, Weedon MN, Knowles JW, Alkayyali S, et al.
Genetic variants associated with glycine metabolism and their role in insulin
sensitivity and type 2 diabetes. Diabetes. 2013;62:2141–50.
16. Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, et al. An
atlas of genetic influences on human blood metabolites. Nat Genet. 2014;
46:543–50.
17. Gantner ML, Eade K, Wallace M, Handzlik MK, Fallon R, Trombley J, et al.
Serine and lipid metabolism in macular disease and peripheral neuropathy.
N Engl J Med. 2019; Available from: https://doi.org/10.1056/NEJMoa1815111.
18. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Wang JJ, et al. Medical
characteristics of patients with macular telangiectasia type 2 (MacTel Type
2) MacTel project report no. 3. Ophthalmic Epidemiol. 2013;20:109–13.
19. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for
causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89–
98.
20. Ebrahim S, Davey SG. Mendelian randomization: can genetic epidemiology
help redress the failures of observational epidemiology? Hum Genet. 2008;
123:15–33.
21. Evans DM, Davey SG. Mendelian randomization: new applications in the
coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet.
2015;16:327–50.
22. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V,
et al. Large-scale association analysis provides insights into the genetic
architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:
981–90.
23. Wittemans LBL, Lotta LA, Oliver-Williams C, Stewart ID, Surendran P,
Karthikeyan S, et al. Assessing the causal association of glycine with risk of
cardio-metabolic diseases. Nat Commun. 2019;10:1060.
24. Lotta LA, et al. A cross-platform approach identifies genetic regulators of
human metabolism and health. Nat Genet. 2021;53(1):54–64. Available from:
https://www.nature.com/articles/s41588-020-00751-5.
25. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
instrumental variables in Mendelian randomization: comparison of allele
score and summarized data methods. Stat Med. 2016;35:1880–906.
26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression.
Int J Epidemiol. 2015;44:512–25.
27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet. 2007;81:559–75.
28. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping
and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.
29. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al.
LocusZoom: regional visualization of genome-wide association scan results.
Bioinformatics. 2010;26:2336–7.
30. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, et al.
Baseline characteristics of participants in the natural history study of
macular telangiectasia (MacTel) MacTel project report no. 2. Ophthalmic
Epidemiol. 2010;17:66–73.
31. Mathew R, Sivaprasad S, Florea D, Leung I, Sallo F, Clemons T, et al.
Agreement between time-domain and spectral-domain optical coherence
tomography in the assessment of macular thickness in patients with
idiopathic macular telangiectasia type 2. Ophthalmologica. 2013;230:144–50.
32. Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures
that control the false discovery rate. Biometrika. 2006;93:491–507.
33. metabolomics gwas server [Internet]. [cited 2018 Dec 4]. Available from:
http://metabolomics.helmholtz-muenchen.de/gwas/
34. Gao XR, Huang H, Kim H. Genome-wide association analyses identify 139
loci associated with macular thickness in the UK Biobank cohort. Hum Mol
Genet. 2018; Available from: https://doi.org/10.1093/hmg/ddy422.
35. Madelaine R, Notwell JH, Skariah G, Halluin C, Chen CC, Bejerano G, et al. A
screen for deeply conserved non-coding GWAS SNPs uncovers a MIR-9-2
functional mutation associated to retinal vasculature defects in human.
Nucleic Acids Res. 2018; Available from: https://doi.org/10.1093/nar/gky166.
36. Mao C-A, Kiyama T, Pan P, Furuta Y, Hadjantonakis A-K, Klein WH.
Eomesodermin, a target gene of Pou4f2, is required for retinal ganglion cell
and optic nerve development in the mouse. Development. 2008;135:271–
80.
37. Pushkin A, Abuladze N, Lee I, Newman D, Hwang J, Kurtz I. Mapping of the
human NBC3 (SLC4A7) gene to chromosome 3p22. Genomics. 1999;57:321–
2.
38. Riebeling C, Allegood JC, Wang E, Merrill AH Jr, Futerman AH. Two
mammalian longevity assurance gene (LAG1) family members, trh1 and
trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA
donors. J Biol Chem. 2003;278:43452–9.
39. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-
Salvadó J, et al. Metabolomics in prediabetes and diabetes: a systematic
review and meta-analysis. Diabetes Care. 2016;39:833–46.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bonelli et al. Genome Medicine           (2021) 13:39 Page 11 of 11
